ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

ASCO 2011 Award Winners

June 10, 2011

CCOPS Unhappy With NCI Policy Limiting Their Participation In Early Phase 2 Clinical Trials

November 11, 1983

Carter Request Only $878.8 Million For NCI

January 27, 1978

Cancer Research Institute Goes To Wall Street

January 17, 1986

Moloney Out As Viral Oncology Chief, Names “Acting Assistant Director” Of NCI By Upton

January 6, 1978

West Virginia CCOP Will Be Funded; NASAU Joins Cincinnati As The Two Cut For Slow Patient Accrual

August 31, 1984